Activated Ras as a Therapeutic Target: Constraints on Directly Targeting Ras Isoforms and Wild-Type versus Mutated Proteins
Open Access
- 31 October 2013
- journal article
- review article
- Published by Wiley in ISRN Oncology
- Vol. 2013, 1-14
Abstract
The ability to selectively and directly target activated Ras would provide immense utility for treatment of the numerous cancers that are driven by oncogenic Ras mutations. Patients with disorders driven by overactivated wild-type Ras proteins, such as type 1 neurofibromatosis, might also benefit from progress made in that context. Activated Ras is an extremely challenging direct drug target due to the inherent difficulties in disrupting the protein:protein interactions that underlie its activation and function. Major investments have been made to target Ras through indirect routes. Inhibition of farnesyl transferase to block Ras maturation has failed in large clinical trials. Likely reasons for this disappointing outcome include the significant and underappreciated differences in the isoforms of Ras. It is still plausible that inhibition of farnesyl transferase will prove effective for disease that is driven by activated H-Ras. The principal current focus of drugs entering clinic trial is inhibition of pathways downstream of activated Ras, for example, trametinib, a first-in-class MEK inhibitor. The complexity of signaling that is driven by activated Ras indicates that effective inhibition of oncogenic transduction through this approach will be difficult, with resistance being likely to emerge through switch to parallel pathways. Durable disease responses will probably require combinatorial block of several downstream targets.Keywords
Funding Information
- National Cancer Institute (R01 CA81150, R01 CA131990, NF990035, NF020054, NF043107, NF093146)
- National Cancer Institute (R01 CA81150, R01 CA131990, NF990035, NF020054, NF043107, NF093146)
- U.S. Army (R01 CA81150, R01 CA131990, NF990035, NF020054, NF043107, NF093146)
- U.S. Army (R01 CA81150, R01 CA131990, NF990035, NF020054, NF043107, NF093146)
- U.S. Army (R01 CA81150, R01 CA131990, NF990035, NF020054, NF043107, NF093146)
- U.S. Army (R01 CA81150, R01 CA131990, NF990035, NF020054, NF043107, NF093146)
This publication has 216 references indexed in Scilit:
- Discovery of Small Molecules that Bind to K‐Ras and Inhibit Sos‐Mediated ActivationAngewandte Chemie International Edition, 2012
- Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancerInvestigational New Drugs, 2012
- Lovastatin regulates brain spontaneous low-frequency brain activity in Neurofibromatosis type 1Neuroscience Letters, 2012
- An orthosteric inhibitor of the Ras-Sos interactionNature Chemical Biology, 2011
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationNature, 2010
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaNature, 2010
- Modulation of the inhibitor properties of dipeptidyl (acyloxy)methyl ketones toward the CaaX proteasesBioorganic & Medicinal Chemistry, 2010
- The Hypervariable Region of K-Ras4B Is Responsible for Its Specific Interactions with CalmodulinBiochemistry, 2009
- How does the Schwann cell lineage form tumors in NF1?Glia, 2008
- Tumour maintenance is mediated by eNOSNature, 2008